HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hirudin in acute coronary syndromes.

Abstract
Acute coronary syndromes are a major cause of morbidity and mortality in Western societies. The term describes a spectrum from unstable angina, the recently defined non-Q wave infarction (the Non ST-Elevation Myocardial Infarction [NSTEMI]), to acute transmural myocardial infarction. With regard to treatment, a series of recently published studies compared the specific direct thrombin inhibitor hirudin with standard unfractionated heparin. Initial small studies showed promising results and led to the initiation of large-scale clinical trials addressing patients with acute coronary syndromes. However, in these studies, an unacceptably high incidence of serious hemorrhagic complications prompted safety boards to stop trials. In those studies carried out according to the protocol, no significant clinical benefit of hirudin over standard heparin was proved. Here, hirudin has been shown to be equivalent to unfractionated heparin for the treatment of unstable coronary syndromes with or without ST elevation and as an adjunct to percutaneous coronary balloon angioplasty. Because of its narrow therapeutic window between clinical benefit and increased bleeding hazards, hirudin should be used cautiously. For patients with heparin-induced thrombocytopenia, hirudin is accepted as an important therapeutic alternative.
AuthorsAndreas van de Loo, Christoph Bode
JournalSeminars in thrombosis and hemostasis (Semin Thromb Hemost) Vol. 28 Issue 5 Pg. 459-66 (Oct 2002) ISSN: 0094-6176 [Print] United States
PMID12420242 (Publication Type: Journal Article, Review)
Chemical References
  • Fibrinolytic Agents
  • Recombinant Proteins
  • Heparin
Topics
  • Angioplasty, Balloon
  • Clinical Trials as Topic
  • Coronary Disease (drug therapy)
  • Fibrinolytic Agents (pharmacology)
  • Heparin (pharmacology)
  • Hirudin Therapy
  • Humans
  • Myocardial Infarction (drug therapy)
  • Recombinant Proteins (pharmacology)
  • Thrombocytopenia (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: